Discovery and Validation of Breast Cancer Early Detection Biomarkers in Preclinical Samples

Hormones and Cancer

Volumn 2, Issue 2, 2011, Pages 125-131

  Li, Christopher I ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; Estrogen receptor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRONECTIN; FIBRONECTIN 1; LACTOFERRIN; PROTEIN NOV HOMOLOG; SOMATOMEDIN BINDING PROTEIN 1; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952622355     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0061-3     Document Type: Article

References (23)

1. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S (1993) Report of the International Workshop on Screening for Breast cancer. J Natl Cancer Inst 85: 1644-1656.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
3. Hortobagyi GN, de la Garza SJ, Pritchard K et al (2005) The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6: 391-401.
4. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW (1982) Infiltrating lobular carcinoma of the breast. Histopathology 6: 149-161.
5. Yeatman TJ, Cantor AB, Smith TJ et al (1995) Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222: 549-559.
6. Silverstein MJ, Lewinsky BS, Waisman JR et al (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73: 1673-1677.
7. Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91: 2020-2028.
8. Krecke KN, Gisvold JJ (1993) Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 161: 957-960.
9. Collett K, Stefansson IM, Eide J et al (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomark Prev 14: 1108-1112.
10. The Women's Health Initiative Study Group (1998) Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19: 61-109.
11. Hays J, Hunt JR, Hubbell FA et al (2003) The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13: S18-S77.
12. Katayama H, Paczesny S, Prentice R et al (2009) Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 1: 47.
13. Pitteri SJ, Amon LM, Buson TB, Zhang Y, Johnson MM, Chin A, Kennedy J, Wong C-H, Zhang Q, Wang H, Lampe PD, Prentice RL, McIntosh MW, Hanash SM, Li CI (2010) Detection of elevated plasma levels of epidermal growth factor receptor prior to breast cancer diagnosis among hormone therapy users. Cancer Res 70: 8598-8606.
14. Thompson IM, Ankerst DP, Chi C et al (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3. 0 ng/ml or lower. JAMA 294: 66-70.
15. Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91: 1532-1542.
16. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y (2002) Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8: 3454-3460.
17. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K (2003) Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80: 353-361.
18. Asgeirsson KS, Agrawal A, Allen C et al (2007) Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 9: R75.
19. Muller V, Witzel I, Pantel K et al (2006) Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res 26: 1479-1487.
20. Souder C, Leitzel K, Ali SM et al (2006) Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer 107: 2337-2345.
21. Lafky JM, Baron AT, Cora EM et al (2005) Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 65: 3059-3062.
22. Hudelist G, Kostler WJ, Gschwantler-Kaulich D et al (2006) Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur J Cancer 42: 186-192.
23. Witzel I, Thomssen C, Krenkel S et al (2006) Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers 21: 131-140.